CD226 anticorps (PE)

N° du produit ABIN2663189

Cet anticorps anti-CD226 est un anticorps Rat Monoclonal détectant CD226 dans FACS, IHC et ICC. Adapté pour Souris.

Aperçu rapide pour CD226 anticorps (PE) (ABIN2663189)

Antigène: CD226

Reactivité: Souris

Hôte: Rat

Clonalité: Monoclonal

Conjugué: Cet anticorp CD226 est conjugé à/à la PE

Application: Flow Cytometry (FACS), Immunohistochemistry (IHC), Immunocytochemistry (ICC)

Clone: TX42-1

Détail du produit anti-CD226 anticorps (PE)

Purification: The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions. The solution is free of unconjugated PE and unconjugated antibody.

Isotype: IgG2a

Information d'application

Indications d'application: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Stockage

Concentration: 0.2 mg/mL

Buffer: Phosphate-buffered solution, pH 7.2, containing 0.09 % sodium azide.

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Conseil sur la manipulation: Protect from prolonged exposure to light. Do not freeze.

Stock: 4 °C

Stockage commentaire: The antibody solution should be stored undiluted between 2°C and 8°C.

Détails sur CD226

Antigène: CD226

Autre désignation: CD226

Sujet: Mouse CD226 (DNAM-1) is a 65 kd glycoprotein of a member of Ig super-family adhesion molecule containing 2 immunoglobulin-like domains. It is associated with leukocyte function associated antigen-1 (LFA-1) involving in TCR-mediated signal transduction for T cell proliferation and differentiation. CD226 is also involved in NK cell and T cell mediated cytotoxicity against certain tumors. CD226 (DNAM-1) is constitutively expressed on naive CD8+ and CD4+ T cells, macrophages, and NK cells. It was reported that CD226 expression is up-regulated on Th1 cells, but down-regulated on Th2 and Th0 cells. CD155 and CD112 are the ligands for CD226.

Pathways: Regulation of Leukocyte Mediated Immunity, Positive Regulation of Immune Effector Process, Cancer Immune Checkpoints